Den tyske producent af corona-vaccinen, BioNTech, har haft en forrygende fremgang i indtjeningen under pandemien. Indtjeningen blev på 5,3 milliarder euro mod forventet 3,5 mia. i andet kvartal, og selskabet venter en indtjening for hele året på 15,9 milliarder euro. For de første seks måneder i år blev nettooverskuddet på 3,9 milliarder euro.

Uddrag fra Saxo Bank: 

Market Quick Take – August 10, 2021

BioNTech raises outlook. The US/German biotechnology company delivered Q2 revenue of $5.31bn vs est. $3.5bn and raised its FY revenue outlook to $15.9bn.

The company said that its vaccine manufacturing capacity is 3bn doses and will be raised to 4bn.

BioNTech also said that many studies show that its Covid19 vaccine has good effectiveness against many different variants and is now negotiating booster shots with several governments.

There was no update on other drug discoveries related to its mRNA technology. Shares were up 15% yesterday.